The American Diabetes Association and the European Association for the Study of Diabetes now recommend GLP-1 RAs as a preferred option for patients with T2DM and established atherosclerotic CVD or high cardiovascular risk [2,3]. This evidence concerns the gene GLP1R and diabetes mellitus.